JPRN-UMIN000013461已完成未知
Combination therapy with a molecular target drug and iron chelator for the treatment of intractable hepatocellular carcinoma - Combination chemotherapy for the treatment of hepatocellular carcinoma
Department of Gastroenterology, Okayama University Hospital0 个研究点目标入组 10 人开始时间: 2014年3月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •active double cancers severe complications contraindication of the test drugs
研究者
相似试验
招募中
不适用
Combination of molecularly-targeted therapy with stereotactic body radiotherapy in hepatocellular carcinoma with major vascular invasioHepatocellular carcinoma with major vascular invasionJPRN-UMIN000030718Osaka International Cancer Institute20
已完成
4 期
Combination drug therapy for fibromyalgia paiMusculoskeletal DiseasesOther soft tissue disorders, not elsewhere classifiedFibromyalgiaISRCTN20173707Queen's University (Canada)69
已完成
不适用
A clinical study of combination drug against type 2 diabetes - Glubes combination tablets for patients poorly controlled with a-GI or Glinidetype2 diabetesJPRN-UMIN000007203Advanced Clinical Research Organization30
已完成
不适用
Combination of checkpoint inhibitor and radiotherapy for recurrent gastric cancer after initial treatment with standard therapy.Gastric cancerJPRN-UMIN000031508Fukushima Medical University41
进行中（未招募）
不适用
Combination of antiangiogenic therapy using the mTOR-inhibitor RAD001 and low dose chemotherapy for locally advanced and/or metastatic pancreatic cancer – a dose finding studyadvanced and/or metastatic pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticEUCTR2006-003403-39-DEovartis Pharma GmbH